Plotkin's Vaccines, 8th Edition

ISBN Number

9780323790581

Main Author

By Walter A. Orenstein, MD, DSc (HON), Paul A. Offit, MD, Kathryn M. Edwards, MD and Stanley A. Plotkin, MD

Trim

276 x 216 (8 1/2 x 10 7/8)

Illustrations

575

Imprint

Elsevier

Page Count

1734

Publication Date

4 Apr 2023

From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field. 

Key Features

Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization. 

Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines. 

Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality. 

Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues. 

Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies. 

Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues. 

Analyzes the cost-benefit and cost-effectiveness of different vaccine options. 

Helps you clearly visualize concepts and objective data through an abundance of tables and figures. 

Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. 

SECTION I

General Aspects of Vaccination

1 A Short History of Vaccination

2 Vaccine Immunology

3 Non-specific Effects of Vaccines

4 Correlates of Protection

5 The Vaccine Industry

6 Vaccine Manufacturing

7 Evolution of Adjuvants Across the Centuries

8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States

9 Passive Immunization

SECTION II

Licenced Vaccines and Vaccines in Development

10 General Immunization Practices

11 Human Adenovirus Vaccines

12 Anthrax Vaccines

13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)

14 Cancer Vaccines

15 Cholera Vaccines

16 Combination Vaccines

17 Coronavirus Vaccines

18 Cytomegalovirus Vaccines

19 Dengue Vaccines

20 Vaccines Against Diarrhea Caused by Noncholera Bacteria

21 Diphtheria Toxoid

22 Ebola Vaccines

23 Nonpolio Enteroviruses

24 Epstein–Barr Virus Vaccines

25 Haemophilus Influenzae Type b Vaccines

26 Hepatitis A Vaccines

27 Hepatitis B Vaccines

28 Hepatitis C Vaccines

29 Hepatitis E Vaccines

30 Herpes Simplex Virus Vaccines

31 Human Immunodeficiency Virus Vaccines

32 Human Papillomavirus Vaccines

33 Inactivated and Recombinant Influenza Vaccines

34 Influenza Vaccine—Live

35 Japanese Encephalitis Vaccines

36 Lyme Disease Vaccines—the Journey Continues

37 Malaria Vaccines

38 Measles Vaccines

39 Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines

40 Meningococcal Vaccines Directed at Capsular Group B

41 Mumps Vaccines

42 Noninfectious Disease Vaccines

43 Norovirus

44 Parasitic Disease Vaccines

45 Pertussis Vaccines

46 Plague Vaccines

47 Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines

48 Pneumococcal Polysaccharide Vaccines

49 Poliovirus Vaccine—Inactivated

50 Poliovirus Vaccine—Live

51 Lyssaviruses and Rabies Vaccines

52 Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies

53 Rotavirus Vaccines

54 Rubella Vaccines

55 Smallpox and Vaccinia

56 Staphylococcus aureus Vaccines

57 Streptococcus Group A Vaccines

58 Streptococcus Group B Vaccines

59 Tetanus Toxoid

60 Tickborne Encephalitis Vaccines

61 Tuberculosis Vaccines

62 Typhoid Fever Vaccines

63 Varicella Vaccines

64 Yellow Fever Vaccine

65 Zika Virus Vaccines

66 Zoster Vaccines

SECTION III

New Technologies

67 Technologies for Making New Vaccines

68 Genetic-Based Vaccine Vectors

69 Technologies to Improve Immunization

SECTION IV

Vaccination of Special Groups

70 Vaccination of Immunocompromised Hosts

71 Vaccines for International Travel

72 Vaccines for Healthcare Personnel

73 Vaccination of Pregnant Women

SECTION V

Public Health and Regulatory Issues

74 Immunization in the United States

75 Immunization in Europe

76 Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region

77 Immunization in Low- and Middle-Income Countries

78 Community Protection

79 Economic Analyses of Vaccine Policies

80 Regulation and Testing of Vaccines in the US

81 Regulation of Vaccines in Europe

82 Regulation of Vaccines in Low- and Middle-Income Countries

83 Vaccine Safety

84 Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake

85 Legal Issues

86 Ethics

ONLINE ONLY

87 Vaccines to Prevent Mpox

APPENDIX

Websites and Applications for Mobile Devices With Information About Immunization

Index

Author Information

By Walter A. Orenstein, MD, DSc (HON), Professor of Medicine and Pediatrics, and Global Health, Emory University; Associate Director, Emory Vaccine Center, Atlanta GA; Bill & Melinda Gates Foundation, Seattle, WA; Former Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta GA ; Paul A. Offit, MD, Chief, Division of Infectious Diseases, Director, Vaccine Education Center, The Children's Hospital of Philadelphia; Professor of Pediatrics, Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Kathryn M. Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics, Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee and Stanley A. Plotkin, MD, Emeritus Professor of Pediatrics, University of Pennsylvania, Emeritus Professor, Wistar Institute, Former Chief, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA; Former Medical and Scientific Director, Pasteur Merieux Connaught (now Sanofi Pasteur), Marnes-la-Coquette, France